



NDA 020130/S-018

SUPPLEMENT APPROVAL

Allergan Pharmaceuticals International, LTD c/o Allergan Sales, LLC
Attention: Jennifer Poon, PharmD
Senior Manager, Global Regulatory Affairs
Harborside Financial Plaza 5
185 Hudson Street, Suite 1900
Jersey City, NJ 07311

Dear Dr. Poon:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 14, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Estrostep® Fe (ethinyl estradiol/norethindrone and ferrous fumarate).

We also refer to our safety labeling change notification letter dated, April 26, 2017, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that you had incorporated into labeling and submitted as a prior approval supplement. On August 9, 2017, a supplement approval letter was sent approving the labeling text. Upon review of the approved labeling text, we had identified that key safety information, listed below, was inadvertently not included in the Precautions section of the label (additions are denoted with an underline):

Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation: Do not co-administer ESTROSTEP Fe with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations (see Warnings, **RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT).**

Therefore, this “Changes Being Effected” supplemental new drug application provides for revisions to the labeling that include the addition of safety information in the Precautions section.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Meredith Hillig, M.S., Safety Regulatory Project Manager, at (301) 796-1218.

Sincerely,

{See appended electronic signature page}

Christine P. Nguyen, M.D.
Acting Director
Division of Bone, Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
10/10/2017